Trivascular Technologies (NASDAQ: TRIV) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Trivascular Technologies to similar companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
This is a summary of current ratings and price targets for Trivascular Technologies and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trivascular Technologies Competitors||128||739||1041||10||2.49|
This table compares Trivascular Technologies and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trivascular Technologies Competitors||-100.14%||-92.44%||-29.75%|
Institutional & Insider Ownership
54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Trivascular Technologies and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Trivascular Technologies Competitors||$1.67 billion||$207.76 million||87.22|
Trivascular Technologies’ peers have higher revenue and earnings than Trivascular Technologies. Trivascular Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Trivascular Technologies peers beat Trivascular Technologies on 8 of the 8 factors compared.
About Trivascular Technologies
Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.
Receive News & Ratings for Trivascular Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trivascular Technologies and related companies with MarketBeat.com's FREE daily email newsletter.